# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and raises the price target from ...
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target...
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell and raises the price target ...
Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target fro...
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lo...